BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 11317966)

  • 1. Management of patients with essential thrombocythemia: current concepts and perspectives.
    Briere J; Guilmin F
    Pathol Biol (Paris); 2001 Mar; 49(2):178-83. PubMed ID: 11317966
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment strategies in essential thrombocythemia. A critical appraisal of various experiences in different centers.
    Barbui T; Finazzi G; Dupuy E; Kiladjian JJ; Brière J
    Leuk Lymphoma; 1996 Sep; 22 Suppl 1():149-60. PubMed ID: 8951786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Primary thrombocythemia: diagnosis and therapy].
    Petrides PE
    Med Klin (Munich); 2006 Aug; 101(8):624-34. PubMed ID: 16896569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment indications and choice of a platelet-lowering agent in essential thrombocythemia.
    Barbui T; Finazzi G
    Curr Hematol Rep; 2003 May; 2(3):248-56. PubMed ID: 12901347
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary thrombocythemia: new drugs for an evolving disease.
    Balduini CL
    Haematologica; 1992; 77(4):297-301. PubMed ID: 1427439
    [No Abstract]   [Full Text] [Related]  

  • 6. [Treatment outcome of patients with essential thrombocythemia at our department in Hungary].
    Iványi JL; Marton É; Plander M; Szendrei T
    Orv Hetil; 2016 Feb; 157(9):336-41. PubMed ID: 26895801
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia.
    Harrison CN; Campbell PJ; Buck G; Wheatley K; East CL; Bareford D; Wilkins BS; van der Walt JD; Reilly JT; Grigg AP; Revell P; Woodcock BE; Green AR;
    N Engl J Med; 2005 Jul; 353(1):33-45. PubMed ID: 16000354
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Anagrelide: what was new in 2004 and 2005?
    Petrides PE
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):399-408. PubMed ID: 16810615
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequela of therapy, or a combination of both?
    Barbui T
    Semin Hematol; 2004 Apr; 41(2 Suppl 3):15-7. PubMed ID: 15190518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Practical approach to treating essential thrombocythaemia: case studies.
    Reilly JT
    Eur J Haematol Suppl; 2007 Oct; (68):40-2. PubMed ID: 17727566
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term incidence of hematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia.
    Kiladjian JJ; Rain JD; Bernard JF; Briere J; Chomienne C; Fenaux P
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):417-21. PubMed ID: 16810617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Essential thrombocythemia.
    Schafer AI
    Prog Hemost Thromb; 1991; 10():69-96. PubMed ID: 2008534
    [No Abstract]   [Full Text] [Related]  

  • 13. Essential thrombocythemia: a retrospective study on the clinical course of 100 patients.
    Chistolini A; Mazzucconi MG; Ferrari A; la Verde G; Ferrazza G; Dragoni F; Vitale A; Arcieri R; Mandelli F
    Haematologica; 1990; 75(6):537-40. PubMed ID: 2098295
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Treatment of essential thrombocythemia].
    Alvarez-Larrán A; Cervantes F; Besses C
    Med Clin (Barc); 2013 Sep; 141(6):260-4. PubMed ID: 23490491
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin in essential thrombocythemia: status quo and quo vadis.
    Griesshammer M; Bangerter M; van Vliet HH; Michiels JJ
    Semin Thromb Hemost; 1997; 23(4):371-7. PubMed ID: 9263354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
    Tefferi A
    Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aspirin and platelet-lowering agents for the prevention of vascular complications in essential thrombocythemia.
    Michiels JJ
    Clin Appl Thromb Hemost; 1999 Oct; 5(4):247-51. PubMed ID: 10726022
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Platelet-mediated erythromelalgic, cerebral, ocular and coronary microvascular ischemic and thrombotic manifestations in patients with essential thrombocythemia and polycythemia vera: a distinct aspirin-responsive and coumadin-resistant arterial thrombophilia.
    Michiels JJ; Berneman Z; Schroyens W; Koudstaal PJ; Lindemans J; Neumann HA; van Vliet HH
    Platelets; 2006 Dec; 17(8):528-44. PubMed ID: 17127481
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Essential thrombocythemia in young adults: major thrombotic complications and complications during pregnancy--a follow-up study in 68 patients.
    Randi ML; Rossi C; Fabris F; Girolami A
    Clin Appl Thromb Hemost; 2000 Jan; 6(1):31-5. PubMed ID: 10726046
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anagrelide reduces thrombotic risk in essential thrombocythaemia vs. hydroxyurea plus aspirin.
    Dombi P; Illés Á; Demeter J; Homor L; Simon Z; Karadi E; Udvardy M; Egyed M
    Eur J Haematol; 2017 Feb; 98(2):106-111. PubMed ID: 27557754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.